Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation (NCT01700751)
This pilot clinical trial studies the safety and maximum tolerated dose of brentuximab vedotin (also known as SGN-035) when given with the immunosuppressive drug tacrolimus (Protopic®; Astellas Pharma US) and methotrexate after unrelated allogeneic donor stem cell transplant in patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes. The addition of brentuximab vedotin to tacrolimus and methotrexate may result in a significant reduction of graft versus host disease in these patients.
This trial is sponsored by Washington University School of Medicine. 
- Condition: Leukemia, Myelodysplastic Syndromes
- Phase: 0
- Estimated Enrollment: 17
- Start: February 2013
- Estimated Completion: August 2017
- Last verified: January 2014
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.